The woman died at Royal Perth Hospital last month.(ABC News: Glyn Jones)

Health authorities have concluded the death of a 61-year-old woman in hospital last month was likely linked to the AstraZeneca COVID-19 vaccine.


The West Australian lady got the antibody toward the beginning of June and was conceded to Royal Perth Hospital soon thereafter, where she passed on of a blood issue. 


The government's Therapeutic Goods Administration (TGA) examined the lady's passing, with an outside antibody wellbeing examination gathering of specialists considering the immunization the possible reason. 

It put together that decision with respect to a solid absence of proof for different causes and the time period inside which she kicked the bucket subsequent to taking the immunization.


The TGA said the lady had encountered a viral disease that might have hypothetically caused the turmoil, yet the gathering felt the uncommon seriousness of the occasion made the antibody an almost certain reason. 


The lady endured Immune Thrombocytopenic Purpura (ITP), which causes low blood platelet levels. 


The connection among ITP and the antibody is as yet being explored, however primer exploration proposes the danger is around one case for each 100,000 AstraZeneca dosages. 


Incidental effects and passings connected to COVID-19 immunizations in Australia remain incredibly uncommon.

The latest report from the Therapeutic Good Administration says there were only 4.4 adverse events reported per 1,000 doses to July 4, with the vast majority of those being minor issues such as headaches and muscle pain.

Blood disorders are far more rare, and the vast majority of those do not end up fatal.

Confusion remains over vaccine

Australia has administered five million doses of the AstraZeneca vaccine.

Confusion around the vaccine has been rife in recent weeks, after a number of mixed messages at top levels. 

Prime Minister Scott Morrison last week announced any Australian adult who wanted the AstraZeneca vaccine could request it from their GP, advice that was disputed by some state officials.

The recommended age for AstraZeneca was raised to 60 last month.

The Australian Technical Advisory Group on Immunisation (ATAGI) did not change its advice after Mr Morrison's intervention.

On July 1 ATAGI reinforced the importance of completing a two-dose schedule with AstraZeneca to ensure maximum protection.